Fiscal year 2025 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses NVAX in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named NVAX in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| John Jacobs | $792,917 | $0 | $3,545,435 | $3,763,292 | $640,331 | $0 | $114,040 | $8,856,015 |
| President and Chief Executive Officer | ||||||||
| Elaine O'Hara | 561,080 | 0 | 1,330,030 | 1,411,235 | 288,143 | 0 | 97,788 | 3,688,276 |
| Executive Vice President, Chief Strategy Officer | ||||||||
| James Kelly | 572,886 | 0 | 1,019,165 | 1,082,782 | 297,362 | 0 | 14,033 | 2,986,228 |
| Executive Vice President, Chief Financial Officer and Treasurer | ||||||||
| Mark Casey | 577,831 | 0 | 885,375 | 940,823 | 289,660 | 0 | 116,764 | 2,810,453 |
| Executive Vice President, Chief Legal Officer and Corporate Secretary | ||||||||
| Ruxandra Draghia-Akli | 600,000 | 0 | 629,600 | 668,040 | 290,250 | 0 | 115,490 | 2,303,380 |
| Former Executive Vice President, Head of Research & Development | ||||||||
| John Trizzino | 310,016 | 0 | 368,624 | 209,724 | 0 | 0 | 821,586 | 1,709,950 |
| Former President and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| John Jacobs | $8,856,015 | $5,087,461 | $7,301,009 | +3,768,554 |
| Elaine O'Hara | 3,688,276 | 1,638,116 | — | +2,050,160 |
| James Kelly | 2,986,228 | 1,829,489 | 1,503,833 | +1,156,739 |
| Mark Casey | 2,810,453 | 1,062,334 | 1,534,587 | +1,748,119 |
| Ruxandra Draghia-Akli | 2,303,380 | — | — | — |
| John Trizzino | 1,709,950 | 1,633,417 | 1,877,883 | +76,533 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Rachel K. King | Director | 2026-06-18 | A | 21,270 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-18 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-18 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-18 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John W. Shiver | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| John W. Shiver | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-18 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-18 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| David Mott | Director | 2026-06-18 | A | 18,880 | — | — | Common | Form 4 ↗ |
| David Mott | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-18 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Gregg H. Alton | Director | 2026-06-18 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Richard J. Rodgers | Director | 2026-06-18 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Richard Douglas | Director | 2026-06-18 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-18 | A | 14,180 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Margaret G. McGlynn | Director | 2026-06-18 | A | 18,880 | — | — | Common | Form 4 ↗ |
| Rachel K. King | Director | 2026-06-18 | D | 18,880 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2026-06-18 | A | 21,270 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Mark Casey | RSU | 2025-03-03 | — | — | 112,500 | — | $885,375 |
| Ruxandra Draghia-Akli | RSU | 2025-03-03 | — | — | 80,000 | — | 629,600 |
| John Jacobs | OPTION | 2025-03-03 | — | — | 676,000 | — | 3,763,292 |
| Ruxandra Draghia-Akli | OPTION | 2025-03-03 | — | — | 120,000 | — | 668,040 |
| Elaine O Hara | OPTION | 2025-03-03 | — | — | 253,500 | — | 1,411,235 |
| John Jacobs | RSU | 2025-03-03 | — | — | 450,500 | — | 3,545,435 |
| James Kelly | RSU | 2025-03-03 | — | — | 129,500 | — | 1,019,165 |
| James Kelly | OPTION | 2025-03-03 | — | — | 194,500 | — | 1,082,782 |
| Mark Casey | OPTION | 2025-03-03 | — | — | 169,000 | — | 940,823 |
| Elaine O Hara | RSU | 2025-03-03 | — | — | 169,000 | — | 1,330,030 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Mark Casey | $885,375 | $0 | $940,823 | 0.0% |
| Ruxandra Draghia-Akli | 629,600 | 0 | 668,040 | 0.0% |
| John Jacobs | 3,545,435 | 0 | 3,763,292 | 0.0% |
| Elaine O Hara | 1,330,030 | 0 | 1,411,235 | 0.0% |
| James Kelly | 1,019,165 | 0 | 1,082,782 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Elaine O'Hara | Option | 72,348 | 5.57 | — |
| James Kelly | Option | 1,297 | 77.77 | — |
| John Trizzino | Option | 46,777 | 9.01 | — |
| James Kelly | RSU | 12,223 | — | 82,139 |
| Ruxandra Draghia-Akli | RSU | 28,513 | — | 191,607 |
| Mark Casey | RSU | 112,500 | — | 756,000 |
| James Kelly | Option | 21,219 | 6.86 | — |
| Elaine O'Hara | RSU | 80,000 | — | 537,600 |
| Elaine O'Hara | RSU | 19,600 | — | 131,712 |
| James Kelly | RSU | 129,500 | — | 870,240 |
| Mark Casey | RSU | 41,899 | — | 281,561 |
| John Jacobs | RSU | 450,500 | — | 3,027,360 |
| James Kelly | Option | 194,500 | 7.87 | — |
| John Jacobs | Option | 676,000 | 7.87 | — |
| John Trizzino | Option | 1,297 | 77.77 | — |
| Mark Casey | Option | 169,000 | 7.87 | — |
| Ruxandra Draghia-Akli | RSU | 80,000 | — | 537,600 |
| Elaine O'Hara | RSU | 169,000 | — | 1,135,680 |
| John Jacobs | RSU | 83,197 | — | 559,084 |
| James Kelly | RSU | 117,333 | — | 788,478 |
| John Jacobs | Option | 281,251 | 5.39 | — |
| James Kelly | Option | 13,235 | 6.97 | — |
| Elaine O'Hara | Option | 253,500 | 7.87 | — |
| Ruxandra Draghia-Akli | Option | 120,000 | 7.87 | — |
| John Jacobs | RSU | 166,666 | — | 1,119,996 |
| John Trizzino | RSU | 96,000 | — | 645,120 |
| John Trizzino | RSU | 28,890 | — | 194,141 |
| Mark Casey | RSU | 8,000 | — | 53,760 |
Our executive compensation program is designed to attract and retain appropriately qualified and industry experienced executives capable of leading the company to the consistent delivery of our mission, vision, and goals. We maintain a compensation philosophy that rewards executives for Company performance tied to attainment of key performance goals.
| CEO STI target (% of salary) | 85% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-18 | 35,779,461 | 34,858,658 | 737,897 | 50.65% | Passed |
| 2025 | 2025-06-20 | 41,390,651 | 15,830,308 | 530,262 | 72.33% | Passed |
| 2024 | 2024-06-13 | 24,187,672 | 8,695,357 | 11,007,350 | 73.56% | Passed |
| 2023 | 2023-07-11 | 15,695,578 | 3,030,052 | 538,435 | 83.82% | Passed |
| 2022 | 2022-06-16 | 19,618,798 | 6,574,169 | 243,539 | 74.9% | Passed |
| 2021 | 2021-06-17 | 31,917,668 | 8,631,639 | 340,263 | 78.71% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-18 | 50.65%a |
| 2025 | 2025-06-20 | 72.33%b |
| 2024 | 2024-06-13 | 73.56%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “Abstentions and broker non-votes will not be counted as shares voting on this matter and accordingly will have no effect on the approval of this Proposal 3.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 52 : 1 |
|---|---|
| CEO total compensation | $8,856,015 |
| Median employee compensation | $169,449 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| John W. Shiver, Ph.DIndependent · Compensation · Newly elected | $59,987 | $195,011 | $261,547 | — | $0 | $516,545 |
| Charles W. NewtonIndependent · Audit · Newly elected | 45,982 | 190,495 | 255,472 | — | 0 | 491,949 |
| Margaret G. McGlynn, R. PhIndependent | 119,187 | 121,021 | 162,070 | — | 0 | 402,278 |
| Richard J. RodgersIndependent · Audit (Chair) · Compensation | 92,358 | 121,021 | 162,070 | — | 0 | 375,449 |
| David MottIndependent · Board Chair · Compensation (Chair) | 82,500 | 121,021 | 162,070 | — | 0 | 365,591 |
| Richard H. Douglas, Ph.DIndependent · Audit | 81,371 | 121,021 | 162,070 | — | 0 | 364,462 |
| Gregg H. Alton, J.DIndependent · Audit · Nominating/Governance · Capital Allocation | 72,000 | 121,021 | 162,070 | — | 0 | 355,091 |
| Rachel K. KingIndependent · Compensation | 70,000 | 121,021 | 162,070 | — | 0 | 353,091 |
| James F. Young, Ph.DIndependent · Departed during FY | 58,750 | — | — | — | 0 | 58,750 |
| John C. JacobsEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $55,000 |
|---|---|
| Annual equity retainer | $283,091 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $682,135 |
| Equity awards (grant-date value) | $1,111,632 |
| All other compensation | $0 |
| Total cost of the board | $1,793,767 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Novavax names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Novavax.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | $1,000,000 | $19,350,145 | $1,650,014 | $1,147,500 | $23,166,223 |
| 2 | Insmed Incorporated | 2025 | William Lewis | 854,550 | 2,999,940 | 9,000,033 | 1,495,463 | 14,467,393 |
| 3 | Novavax | 2025 | John Jacobs | 792,917 | 3,545,435 | 3,763,292 | 640,331 | 8,856,015 |
| 4 | Amneal Pharmaceuticals Inc. | 2025 | Chirag Patel | 800,000 | 6,974,995 | 0 | 848,000 | 8,691,745 |
| 5 | Bicycle | 2025 | Kevin Lee | 862,339 | 1,724,800 | 2,961,297 | 543,642 | 6,341,473 |
| 6 | Beam Therapeutics Inc. | 2025 | John Evans | 755,000 | 1,513,575 | 2,876,754 | 662,513 | 5,818,525 |
| — | Organogenesis Holdings, Inc. | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Novavax | 95% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| Amneal Pharmaceuticals Inc. | 106% | PSU 65 · RSU 35 | No | Meridian |
| Beam Therapeutics Inc. | 135% | Options 66 · RSU 34 | not disclosed | Pay Governance LLC |
| Bicycle | 97% | not disclosed | not disclosed | not disclosed |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Insmed Incorporated | 175% | Options 75 · RSU 25 | No | Willis Towers Watson (WTW) |
| Organogenesis Holdings, Inc. | not disclosed | not disclosed | not disclosed | not disclosed |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, John Jacobs | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Summary Compensation Table”. As printed: 8,856,015. Filing ↗machine: t197 · r2 · c8 · span 944385–944394 |
| 2 | Section 01, Elaine O'Hara | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “SUMMARY COMPENSATION TABLE”. As printed: 3,688,276. Filing ↗machine: r10 · c24 · span 959901–959910 |
| 3 | Section 01, James Kelly | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “SUMMARY COMPENSATION TABLE”. As printed: 2,986,228. Filing ↗machine: r6 · c24 · span 952171–952180 |
| 4 | Section 01, Mark Casey | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “SUMMARY COMPENSATION TABLE”. As printed: 2,810,453. Filing ↗machine: r13 · c24 · span 965741–965750 |
| 5 | Section 01, Ruxandra Draghia-Akli | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “SUMMARY COMPENSATION TABLE”. As printed: 2,303,380. Filing ↗machine: r21 · c24 · span 982057–982066 |
| 6 | Section 01, John Trizzino | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “SUMMARY COMPENSATION TABLE”. As printed: 1,709,950. Filing ↗machine: r17 · c24 · span 973879–973888 |
| 7 | Section 03, Mark Casey RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r5 · c1 · span 882015–882022 |
| 8 | Section 03, Ruxandra Draghia-Akli RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r6 · c1 · span 882597–882603 |
| 9 | Section 03, John Jacobs OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r2 · c1 · span 875933–875940 |
| 10 | Section 03, Ruxandra Draghia-Akli OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r6 · c1 · span 877991–877998 |
| 11 | Section 03, Elaine O Hara OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r4 · c1 · span 876906–876913 |
| 12 | Section 03, John Jacobs RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r2 · c1 · span 880539–880546 |
| 13 | Section 03, James Kelly RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t181 · r3 · c1 · span 881026–881033 |
| 14 | Section 03, James Kelly OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r3 · c1 · span 876420–876427 |
| 15 | Section 03, Mark Casey OPTION | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t179 · r5 · c1 · span 877409–877416 |
| 16 | Section 03, Elaine O Hara RSU | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Grants of Plan-Based Awards Table” · grants of plan-based awards table. Filing ↗machine: t200 · r13 · c8 · span 1012633–1012642 |
| 17 | Section 07, pay ratio | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “CEO Pay Ratio”. As printed: 52 : 1. Filing ↗machine: t230 · r3 · c1 · span 1235866–1235873 |
| 18 | Section 08, John W. Shiver, Ph.D | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 516,545. Filing ↗machine: t106 · r9 · c4 · span 592136–592143 |
| 19 | Section 08, Charles W. Newton | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 491,949. Filing ↗machine: t106 · r7 · c4 · span 589555–589562 |
| 20 | Section 08, Margaret G. McGlynn, R. Ph | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 402,278. Filing ↗machine: t106 · r5 · c4 · span 586986–586993 |
| 21 | Section 08, Richard J. Rodgers | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 375,449. Filing ↗machine: t106 · r8 · c4 · span 590752–590759 |
| 22 | Section 08, David Mott | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 365,591. Filing ↗machine: t106 · r6 · c4 · span 588175–588182 |
| 23 | Section 08, Richard H. Douglas, Ph.D | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 364,462. Filing ↗machine: t106 · r3 · c4 · span 584586–584593 |
| 24 | Section 08, Gregg H. Alton, J.D | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 355,091. Filing ↗machine: t106 · r2 · c4 · span 583371–583378 |
| 25 | Section 08, Rachel K. King | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 353,091. Filing ↗machine: t106 · r4 · c4 · span 585779–585786 |
| 26 | Section 08, James F. Young, Ph.D | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 58,750. Filing ↗machine: t106 · r10 · c1 · span 592899–592905 |
| 27 | Section 08, John C. Jacobs | DEF 14A | 2026-04-27 | 0001628280-26-027328 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 28 | Section 02, Rachel K. King 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Margaret G. McGlynn 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, David Mott 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Richard J. Rodgers 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Richard J. Rodgers 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Rachel K. King 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Richard Douglas 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Margaret G. McGlynn 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, David Mott 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Gregg H. Alton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, John W. Shiver 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, John W. Shiver 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076923 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Richard J. Rodgers 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Rachel K. King 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Richard Douglas 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Richard Douglas 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Margaret G. McGlynn 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, David Mott 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, David Mott 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076925 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Gregg H. Alton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Gregg H. Alton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Gregg H. Alton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076924 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Richard J. Rodgers 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076930 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Richard Douglas 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076927 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Charles W. Newton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Margaret G. McGlynn 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076926 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Rachel K. King 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076928 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Charles W. Newton 2026-06-18 | Form 4 | 2026-06-23 | 0001104659-26-076922 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 06, 2026 vote | Form 8-K | 2026-06-23 | 0001104659-26-076648 | Item 5.07 · say-on-pay result. As reported: 50.65% (votes for as printed: 35,779,461). Filing ↗ |
| 57 | Section 06, 2025 vote | Form 8-K | 2025-06-24 | 0001104659-25-061874 | Item 5.07 · say-on-pay result. As reported: 72.33% (votes for as printed: 41,390,651). Filing ↗ |
| 58 | Section 06, 2024 vote | Form 8-K | 2024-06-14 | 0001104659-24-071735 | Item 5.07 · say-on-pay result. As reported: 73.56% (votes for as printed: 24,187,672). Filing ↗ |
| 59 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 60 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 61 | Section 09b board cost (computed) | Computed | — | computed | Cash 682,135 + equity 1,111,632 + all other 0 = 1,793,767, summed across the director compensation table rows.machine: formula: Σ = 1,793,767 |
| 62 | Halozyme Therapeutics, Inc., Section 10b CEO total | DEF 14A | 2026-03-23 | 0001159036-26-000041 | CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. Filing ↗machine: r3 · c48 · span 478282–478292 |
| 63 | Insmed Incorporated, Section 10b CEO total | DEF 14A | 2026-04-01 | 0001104506-26-000022 | CEO total compensation as printed in Insmed Incorporated's own proxy. As printed: 14,467,393. Filing ↗machine: r4 · c51 · span 912553–912563 |
| 64 | Novavax (subject), Section 10b CEO total | DEF 14A | 2026-04-27 | 0001628280-26-027328 | CEO total compensation as printed in Novavax's own proxy. As printed: 8,856,015. Filing ↗machine: t197 · r2 · c8 · span 944385–944394 |
| 65 | Amneal Pharmaceuticals Inc., Section 10b CEO total | DEF 14A | 2026-03-25 | 0001308179-26-000143 | CEO total compensation as printed in Amneal Pharmaceuticals Inc.'s own proxy. As printed: 8,691,745. Filing ↗machine: r4 · c16 · span 470587–470596 |
| 66 | Bicycle, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001104659-26-046806 | CEO total compensation as printed in Bicycle's own proxy. As printed: 6,341,473. Filing ↗machine: t83 · r5 · c14 · span 491024–491033 |
| 67 | Beam Therapeutics Inc., Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-161512 | CEO total compensation as printed in Beam Therapeutics Inc.'s own proxy. As printed: 5,818,525. Filing ↗machine: r2 · c29 · span 502169–502178 |
| 68 | Section 10a, Insmed Incorporated reciprocity | DEF 14A | — | 0001104506-26-000022 | Insmed Incorporated's most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 69 | Section 10a, Halozyme Therapeutics, Inc. reciprocity | DEF 14A | — | 0001159036-26-000041 | Halozyme Therapeutics, Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |
| 70 | Section 10a, Beam Therapeutics Inc. reciprocity | DEF 14A | — | 0001193125-26-161512 | Beam Therapeutics Inc.'s most recent proxy was read; its disclosed peer group does not include Novavax. Filing ↗ |